These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 21129130

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
    Baleriola C, Rawlinson WD, Dore GJ, Chaverot S, Stelzer-Braid S, Yoshihara M, Crawford D, Sievert W, McCaughan G, Weltman M, Cheng W, Rizkalla B, Dubois D, Thommes J, Roberts S.
    Antivir Ther; 2011; 16(2):173-80. PubMed ID: 21447866
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [Abstract] [Full Text] [Related]

  • 4. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.
    AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
    He LL, Chen Z, Chen Y, Xu H, Tang H, Lei BJ, Lei XZ.
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jan 02; 19(1):34-7. PubMed ID: 21272456
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, Shebl FM, Amer AM, Butt MT, Yakoob R, John A, Al Mohanadi M, Al Khinji MA.
    J Viral Hepat; 2008 Aug 02; 15(8):591-9. PubMed ID: 18482284
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
    Liu JP, Kang Y, Shang J, Ding GQ, Xiao EH, Wei JF, Cao Q.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Sep 02; 21(9):656-8. PubMed ID: 24160338
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.